Who are Cyclosporine NOVA22007 0.05%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, Mycophenolate+Tacrolimus+Prednisone, Herombopag + CsA, CsA+Herombopag, Cyclosporin (CSA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyclosporine-nova22007-0-05.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cyclosporine NOVA22007 0.05% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cyclosporine NOVA22007 0.05% (Cyclosporine NOVA22007 0.05%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor. Area: Ophthalmology.

phase 2 Calcineurin inhibitor Calcineurin Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Cyclosporine NOVA22007 0.05% (Cyclosporine NOVA22007 0.05%) — Santen SAS. Cyclosporine is an immunosuppressant that inhibits calcineurin, thereby reducing T-cell activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclosporine NOVA22007 0.05% TARGET	Cyclosporine NOVA22007 0.05%	Santen SAS	phase 2	Calcineurin inhibitor	Calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Mycophenolate+Tacrolimus+Prednisone	Mycophenolate+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)
Herombopag + CsA	Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist + Calcineurin inhibitor	TPO receptor (c-Mpl) + Calcineurin
CsA+Herombopag	CsA+Herombopag	Peking Union Medical College Hospital	marketed	Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist	Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag)
Cyclosporin (CSA)	Cyclosporin (CSA)	Eastern Cooperative Oncology Group	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (Calcineurin inhibitor class)

Novartis · 4 drugs in this class
Astellas Pharma Inc · 4 drugs in this class
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · 4 drugs in this class
University of Cincinnati · 3 drugs in this class
Allergan · 3 drugs in this class
Astellas Pharma China, Inc. · 3 drugs in this class
Novaliq GmbH · 3 drugs in this class
Hoffmann-La Roche · 3 drugs in this class
LEO Pharma · 3 drugs in this class
Santen SAS · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyclosporine NOVA22007 0.05% — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclosporine-nova22007-0-05. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab